The use of inter partes review (IPR) to challenge bio/pharma patents has grown significantly — with the number nearly doubling in 2015 alone. While relatively few of them have reached final decisions, what gives some challengers the winning edge?
Please join our experienced attorneys for a discussion on the key challenges you could face with your next IPR, as well as your overall strategies for patent litigation and enforcement, and how to prepare to address them.
Stephen Maebius, Partner, IP Department, Foley & Lardner LLP
Kristel Schorr, Partner and Chair, Chemical, Biotechnology & Pharmaceutical Practice, Foley & Lardner LLP
Etsuo Doi, Managing Partner, Tokyo Office, Foley & Lardner LLP
